NCT04340388View on ClinicalTrials.gov

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

June 17, 2022

Study Completion Date

February 25, 2023

Conditions
HIV-1-infectionAntiviral Drug Adverse ReactionVascular DiseasesCardiovascular AbnormalitiesAbnormality of Adipose TissueBody Weight ChangesBody Fat DisorderHIV-Associated Lipodystrophy Syndrome
Interventions
DRUG

Dolutegravir 50 MG

15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.

DRUG

Antiretroviral/Anti HIV

15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.

Trial Locations (1)

30912

Augusta University, Augusta

All Listed Sponsors
lead

Augusta University

OTHER

NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease | Biotech Hunter | Biotech Hunter